Regression of portal hypertension: underlying mechanisms and therapeutic strategies.

Selicean, Sonia; Wang, Cong; Guixé-Muntet, Sergi; Stefanescu, Horia; Kawada, Norifumi; Gracia-Sancho, Jordi (2021). Regression of portal hypertension: underlying mechanisms and therapeutic strategies. Hepatology international, 15(1), pp. 36-50. Springer 10.1007/s12072-021-10135-4

Preview

Text 12072_2021_Article_10135.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (1MB) | Preview

Portal hypertension is the main non-neoplastic complication of chronic liver disease, being the cause of important life-threatening events including the development of ascites or variceal bleeding. The primary factor in the development of portal hypertension is a pathological increase in the intrahepatic vascular resistance, due to liver microcirculatory dysfunction, which is subsequently aggravated by extra-hepatic vascular disturbances including elevation of portal blood inflow. Evidence from pre-clinical models of cirrhosis has demonstrated that portal hypertension and chronic liver disease can be reversible if the injurious etiological agent is removed and can be further promoted using pharmacological therapy. These important observations have been partially demonstrated in clinical studies. This paper aims at providing an updated review of the currently available data regarding spontaneous and drug-promoted regression of portal hypertension, paying special attention to the clinical evidence. It also considers pathophysiological caveats that highlight the need for caution in establishing a new dogma that human chronic liver disease and portal hypertension is reversible.

Interest & Impact

Downloads

54 since deposited on 27 Oct 2021
16 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item